Regeneron Pharmaceuticals Inc. buy Oppenheimer Holdings Inc.
Start price
06.11.24
/
50%
€768.80
Target price
06.11.25
€933.10
Performance (%)
-26.66%
End price
07.11.25
€563.80
Summary
This prediction ended on 07.11.25 with a price of €563.80. The price of Regeneron Pharmaceuticals Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -26.66%. Dividends of €2.60 are taken into consideration when calculating the performance. Oppenheimer_Holdings has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 1.137% | 1.137% | -3.348% |
| iShares Core DAX® | 2.331% | 5.140% | 25.000% |
| iShares Nasdaq 100 | 2.077% | 2.956% | 8.935% |
| iShares Nikkei 225® | 2.759% | 7.214% | 22.171% |
| iShares S&P 500 | 1.613% | 2.893% | 6.249% |
Comments by Oppenheimer_Holdings for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $1,150.00 to $1,000.00. They now have an "outperform" rating on the stock.
Ratings data for REGN provided by MarketBeat
In the thread Trading Regeneron Pharmaceuticals Inc.
Die von Oppenheimer_Holdings gewählte maximale Laufzeit wurde überschritten